Libri di Eric S. Orwoll

Since the publication of the first edition, the U.S. Surgeon General released the first-ever report on bone health and osteoporosis in October 2004. This report focuses even more attention on the devastating impact osteoporosis has on millions of lives. According to the National Osteoporosis Foundation, 2 million American men have osteoporosis, and another 12 million are at risk for this disease. Yet despite the large number of men affected, the lack of awareness by doctors and their patients puts men at a higher risk that the condition may go undiagnosed and untreated. It is estimated that one-fifth to one-third of all hip fractures occur in men. This second edition brings on board John Bilezikian and Dirk Vanderschueren as editors with Eric Orwoll. The table of contents is more than doubling with 58 planned chapters. The format is larger - 8.5 x 11. This edition of "Osteoporosis in Men" brings together even more eminent investigators and clinicians to interpret developments in this growing field, and describe state-of-the-art research as well as practical approaches to diagnosis, prevention, and therapy. The key features of the book include: brings together more eminent investigators and clinicians to interpret developments in this growing field; describes state-of-the-art research as well as practical approaches to diagnosis, prevention and therapy; and there is no book on the market that covers osteoporosis in men as comprehensively as this book.

In "Osteoporosis: Pathophysiology and Clinical Management", leading clinicians and researchers join forces to illuminate in coupled chapters all the major scientific and clinical aspects of osteoporosis. On the basic science side, topics range from the genetics of osteoporosis and bone turnover markers, to androgen action in bone, to the basic biology of estrogen and bone. On the clinical side, the authors present the latest thinking about the use of bone densitometry in treatment, the use of vitamin D and its metabolites, and the clinical utilization of salmon calcitonin, as well as parathyroid and bisphosphonate therapies, SERMs, and other important treatments.